Doses - PYRIDOSTIGMINE BROMIDE
Dogs: 
For myasthenia gravis (MG): a) For acquired MG: After oral regurgitation is abolished with parenteral therapy(neostigmine), may begin oral therapy with pyridostigmine at 7.5 - 30 mg PO bid. Oncepatient is stable and infections have resolved, begin corticosteroid therapy(antiinflammatory doses of prednisone) and continue concurrently with anticholinesterase drugs for 2 weeks. Then pyridostigmine may be gradually reduced.(Pedroia 1989)
b) Proven efficacy for acquired MG, but of questionable value for congenital MG.
Pyridostigmine: 0.2 - 2 mg/kg PO bid-tid. Higher dose is often too high initially.(LeCouteur 1989)
c) Initial guidelines only; titrate dose to the patient. Dogs weighing less than 5 kg: 45 mg
PO qid; weighing 5-25 kg: 45-90 mg PO qid; weighing more than 25 kg: 90 - 135 mg
PO qid. If cholinergic symptoms occur, reduce dose by 25%; atropine rarely necessary.(Hurvitz and Johnessee 1985)
Cats: 
For myasthenia gravis (MG): a) For acquired MG: Cats are sensitive to anticholinesterase agents. Do not exceed 0.25mg/kg/day PO initially in cats. (Fenner 1989)
Monitoring Parameters - Animals should be routinely monitored for symptoms of cholinergictoxicity (see Overdose section above) and also for efficacy of the therapy.
Client Information - See Monitoring above. Clients should be instructed to report to the veterinarian symptoms of excessive salivation, GI disturbances, weakness, or difficulty breathing.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None